Resverlogix Announces Participation in Upcoming Conferences

CALGARY, Sept. 12, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce its participation in the following industry conferences in the month of September.

  • Rodman & Renshaw 18th Annual Global Investment Conference

Location:

New York, NY.

Date:

September 13th, 2016

Presentation Time:

2:10pm EDT

Presenting:

Mr. Donald J. McCaffrey, President & Chief Executive Office

Webcast link:

http://wsw.com/webcast/rrshq26/RVX

 

  • BioPharm America 9th Annual International Partnering Conference

Location:

Boston, MA.

Date:

September 14th, 2016

Presentation Time:

12:00pm EDT

Presenting:

Mr. Kenneth Lebioda, Sr. VP Business & Corporate Development

 

  • 52nd European Association for the Study of Diabetes (EASD) Annual Meeting

Location:            

Munich, Germany

Date:       

September 14th, 2016

Presentation Time:  

12:00pm CEST

Presenting:         

Dr. Norman Wong, Chief Scientific Officer

Poster:            

"Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes patients with atherosclerosis via microbiome activity"

 

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email:
ir@resverlogix.com
Phone: 403-254-9252

SOURCE Resverlogix Corp.

RELATED LINKS
http://www.resverlogix.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890